Workflow
Firefly Neuroscience, Inc.(AIFF)
icon
Search documents
Firefly Neuroscience, Inc.(AIFF) - 2020 Q4 - Annual Report
2021-03-31 19:55
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-22405 Information Analysis Incorporated (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...
Firefly Neuroscience, Inc.(AIFF) - 2020 Q3 - Quarterly Report
2020-11-16 16:33
Revenue Performance - Revenue for Q3 2020 was $3,922,746, an increase of $740,149 or 23.3% compared to Q3 2019[78] - Revenue for the first nine months of 2020 was $10,803,897, an increase of $2,738,060 or 33.9% compared to $8,065,837 in the same period of 2019[85] Professional Fee and Software Revenue - Professional fee revenue increased by $692,022 or 77.9% to $1,580,684 in Q3 2020, driven by new contracts[78] - Professional fee revenue increased by $941,099 or 39.0% to $3,353,508 in 2020, while software revenue rose by $1,796,961 or 31.8% to $7,450,389[85] Gross Profit and Expenses - Gross profit for Q3 2020 was $614,328, representing 15.7% of revenue, up from 12.1% in Q3 2019[79] - Gross profit for the first nine months of 2020 was $1,282,171, representing 11.9% of revenue, down from 13.2% in 2019[86] - Selling, general and administrative expenses decreased by $124,889 or 26.7% to $342,778, representing 8.7% of revenues in Q3 2020[80][81] - Selling, general and administrative expenses decreased by $431,933 or 29.2% to $1,049,761, accounting for 9.7% of revenues in 2020[87] Net Income - Net income for Q3 2020 was $214,703, or 5.5% of revenue, compared to a net loss of ($179,224) in Q3 2019[83] - Net income for the nine months ended September 30, 2020, was $53,744, or 0.5% of revenue, compared to a net loss of ($578,679) or (7.2%) in 2019[89] Cash Flow and Financial Position - Net cash provided by operating activities was $38,569, with an overall increase in cash and cash equivalents of $429,929, totaling $1,469,371 at September 30, 2020[90] - The company received a Paycheck Protection Program loan of $450,000 to support employee payroll and benefits, with plans to apply for forgiveness[92] - The company has a revolving line of credit of up to $1,000,000, with no amounts outstanding as of September 30, 2020[91] - The company anticipates being able to meet its cash requirements for at least one year from the filing date of the Quarterly Report[93] Strategic Focus and Market Conditions - The company is refocusing its strategy to pursue targeted markets and explore growth through strategic acquisitions[69] - The commencement of delayed contracts, including a significant subcontract, positively impacted revenue and net income[84] - The company recognizes the urgent need for IT modernization in federal and state agencies due to challenges highlighted by the coronavirus pandemic[68] Revenue Concentration Risks - Prime contracts with U.S. government agencies generated 54.1% of revenue in Q3 2020, while subcontracts generated 44.8%[71] - One software sales contract accounted for 12.1% of total revenue in Q3 2020, highlighting revenue concentration risks[71] Internal Control - There were no changes in the company's internal control over financial reporting that materially affected its effectiveness during the quarter ended September 30, 2020[98]
Firefly Neuroscience, Inc.(AIFF) - 2020 Q2 - Quarterly Report
2020-08-14 18:14
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-22405 Information Analysis Incorporated (Exact name of registrant as specified in its charter) Virginia 54-1167364 (State or oth ...
Firefly Neuroscience, Inc.(AIFF) - 2020 Q1 - Quarterly Report
2020-05-15 17:29
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-22405 Information Analysis Incorporated (Exact name of registrant as specified in its charter) Virginia 54-1167364 (State or ot ...
Firefly Neuroscience, Inc.(AIFF) - 2019 Q4 - Annual Report
2020-03-30 19:53
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 11240 Waples Mill Road Suite 201 Fairfax, Virginia 22030 (Address of principal executive of ices) (703) 383-3000 Registrant's telephone number, including area code ...
Firefly Neuroscience, Inc.(AIFF) - 2019 Q3 - Quarterly Report
2019-11-14 19:20
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-22405 Information Analysis Incorporated (Exact name of registrant as specified in its charter) Virginia 54-1167364 (State o ...
Firefly Neuroscience, Inc.(AIFF) - 2019 Q2 - Quarterly Report
2019-08-14 18:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-22405 Information Analysis Incorporated (Exact name of registrant as specified in its charter) Virginia 54-116 ...
Firefly Neuroscience, Inc.(AIFF) - 2019 Q1 - Quarterly Report
2019-05-15 20:14
Information Analysis Incorporated Form 10-Q First Quarter 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-22405 Information Analysis Incorporated (Exact name of registrant as specifie ...
Firefly Neuroscience, Inc.(AIFF) - 2018 Q4 - Annual Report
2019-04-01 19:24
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Virginia 54-1167364 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 11240 Waples Mill Road Suite 201 Fairfax ...